Not a good buy right now: price is in a clear short-term downtrend with bearish momentum (MACD histogram negative and worsening).
RSI is extremely oversold (RSI_6 ~12.8), but there is no confirmed reversal signal (and the stock is trading below key support), so this still looks like a “falling knife” setup.
Analyst targets imply meaningful upside vs. $12.46, but near-term tape is weak and there are no Intellectia buy signals to justify an impatient entry today.
Best stance now: hold/avoid new buys until price reclaims key support (~$12.73) and momentum stabilizes.
Technical Analysis
Trend/Momentum: Bearish. MACD histogram at -0.225 and negatively expanding signals strengthening downside momentum.
RSI: RSI_6 at ~12.81 indicates deeply oversold conditions; a bounce is possible, but oversold alone is not a buy trigger without confirmation.
Moving Averages: Converging MAs suggest consolidation risk, but with current momentum skewed downward.
Key levels: Current ~$12.455 is below S1 ($12.733); next support is S2 ($11.926). Resistance/pivot area near $14.039; upside levels $15.346 then $16.153.
Pattern-based probability: Similar-pattern model suggests modest further downside bias (next day -0.76%, next week -0.75%, next month -3.99%).
Positive Catalysts
sit well above current price, implying potential re-rating if execution improves.
Neutral/Negative Catalysts
increases risk of a move toward $11.
No near-term news flow in the past week to interrupt the trend.
Financial Performance
Latest quarter: 2026/Q2.
Growth: Essentially flat YoY across key lines (Revenue $669.187M, Net Income $105.284M, EPS $0.57 all showing 0.00% YoY change per snapshot), indicating limited near-term acceleration.
Margins: Gross margin reported at 68.14% (stable per snapshot), supportive, but not currently translating into visible growth momentum.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent tone: Generally constructive (Buy/Overweight/Outperform) with one Neutral; however, multiple firms adjusted targets downward or kept them conservative, reflecting tempered expectations.
Goldman Sachs (2025-12-22): Buy; PT cut to $22 from $25; positive on K-12 share gains and AI positioning, flags mix/margin headwinds and legacy product phase-outs.
Morgan Stanley (2025-12-17): Overweight; PT raised to $21 from $20; highlights AI as a key differentiator theme.
BMO (2025-11-13): Outperform; PT cut to $21 from $25 post “beat and raise,” but moderated upside assumptions.
UBS (2025-11-13): Neutral; PT raised to $16 from $15.
Wall Street pros: Strong K-12 momentum, improving capture rates, AI leverage.
Wall Street cons: Mix-driven margin pressure, slower Global Professional outlook, and legacy product runoff.
Wall Street analysts forecast MH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MH is 20.13 USD with a low forecast of 16 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast MH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MH is 20.13 USD with a low forecast of 16 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.130
Low
16
Averages
20.13
High
22
Current: 12.130
Low
16
Averages
20.13
High
22
Goldman Sachs
Buy
maintain
$25 -> $22
AI Analysis
2025-12-22
Reason
Goldman Sachs
Price Target
$25 -> $22
AI Analysis
2025-12-22
maintain
Buy
Reason
Goldman Sachs lowered the firm's price target on McGraw Hill to $22 from $25 and keeps a Buy rating on the shares. The firm updated its forecasts to reflect stronger K-12 revenue growth in F2026 from market share gains and slower Global Professional growth in FY27-FY28 due to legacy product phase-outs, alongside slightly lower EBITDA margins from a higher mix of lower-margin K-12 and non-core revenue runoff, the analyst tells investors in a research note. The outlook remains positive given share gains in K-12 and Higher Education, rising capture rates outside CA, TX, and FL, expectations for a double-digit K-12 TAM rebound in FY27, and strong AI positioning supported by proprietary content, large-scale learner data, and adaptive learning technologies, Goldman adds.
Morgan Stanley
NULL
to
Overweight
maintain
$20 -> $21
2025-12-17
Reason
Morgan Stanley
Price Target
$20 -> $21
2025-12-17
maintain
NULL
to
Overweight
Reason
Morgan Stanley raised the firm's price target on McGraw Hill to $21 from $20 and keeps an Overweight rating on the shares. 2025 marked a shift in Info Services, bifurcating leaders and laggards in the group based on AI, notes the analyst, who assumes AI will continue to be an important theme in 2026 among the group.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MH
